US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

50.92

+0.10190.20%

Post-market: 50.89-0.0309-0.06%16:05 EDT

Volume:2.74K

Turnover:139.47K

Market Cap:25.46M

PE:- -

High:50.92

Open:50.84

Low:50.84

Close:50.82

Loading ...

Overview Company News Filings

Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Omnicell Introduces OmniSphere Platform, Stock to Gain

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion

Press Release: Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant

Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSF/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":50.9209,"timestamp":1744920000000,"preClose":50.819,"halted":0,"volume":2742,"hourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"delay":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Market Closed","change":0.1019,"latestTime":"04-17 16:00:00 EDT","open":50.84,"high":50.9209,"low":50.84,"amount":139469.3583,"amplitude":0.001592,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":50.819,"sharesOutstanding":500000,"nav":50.919731,"aum":25459850,"bidAskSpread":0.001349,"preHourTrading":{"tag":"盘前","latestPrice":50.819,"preClose":50.819,"latestTime":"08:02 EDT","volume":8,"amount":406.552,"timestamp":1744891358272},"postHourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"volumeRatio":0.3635254778799937},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3635254778799937,"shares":500000,"dividePrice":0.78061,"high":50.9209,"amplitude":0.001592,"preClose":50.819,"low":50.84,"week52Low":47.7503,"pbRate":"--","week52High":60.63,"institutionHeld":0,"latestPrice":50.9209,"eps":0,"divideRate":0.01533,"volume":2742,"delay":0,"ttmEps":0,"open":50.84,"prevYearClose":54.8761,"prevWeekClose":50.7,"prevMonthClose":51.5505,"prevQuarterClose":51.5505,"fiveDayClose":50.55,"twentyDayClose":52.06,"sixtyDayClose":56.7724},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2492127401","title":"Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127401","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127401?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"If approved, UX111 would be the first approved therapy in the U.S. for Sanfilippo Syndrome Type ANOVATO, Calif., Dec.  19, 2024  (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999800/20739/en/Ultragenyx-Submits-Biologics-License-Application-to-the-U-S-FDA-for-UX111-AAV-Gene-Therapy-for-the-Treatment-of-Sanfilippo-Syndrome-Type-A-MPS-IIIA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139","CSF"],"gpt_icon":0},{"id":"2492959911","title":"Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959911","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959911?lang=en_us&edition=fundamental","pubTime":"2024-12-17 20:30","pubTimestamp":1734438600,"startTime":"0","endTime":"0","summary":"Single intrathecal dose of Rhenium (186Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation Both single-dose and multiple-d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998156/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Breast-Cancer-Patients-with-Leptomeningeal-Metastases-at-the-2024-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4202","NCI","CSF","BK4139","LENZ"],"gpt_icon":0},{"id":"2491433680","title":"Omnicell Introduces OmniSphere Platform, Stock to Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2491433680","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491433680?lang=en_us&edition=fundamental","pubTime":"2024-12-12 21:40","pubTimestamp":1734010800,"startTime":"0","endTime":"0","summary":"Omnicell, Inc.OMCL recently introduced OmniSphere, a next-generation, cloud-native software workflow engine and data platform. The new platform is designed to leverage the full power of a cloud-native architecture and seamlessly integrate robotics and smart devices to support more secure, data-driven medication management across the continuum of care.Subsequent to the news, OMCL’s share price moved north marginally by 0.1% to $47.14 Tuesday. Earlier this year, Omnicell announced XT Amplify, a multi-year program intended to maximize the value of XT technology investments. The solutions within the XT Amplify program are OmniSphere. The company’s XT Amplify program has been gaining market momentum with several new customers choosing these offerings. Henceforth, we expect OMCL stock to remain positive surrounding the announcement.Per the Grand View Researchreport, the global medication management system market was valued at $7.07 billion in 2023 and is expected to grow at a compound rate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/omnicell-introduces-omnisphere-platform-stock-134000072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4167","BK4548","RMD","LU1169590202.USD","HAE","BK4567","BK4585","OMCL","BK4588","LU0012050646.USD","BK4198","CSF","PEN","IE00B64QTZ34.USD","IE00BLDYK493.USD","LU0205194284.USD","LU0106261612.USD","LU2177674079.SGD","LU0205193047.USD","LU2008162690.USD","BK4082","LU1169589451.USD"],"gpt_icon":0},{"id":"2490862467","title":"QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2490862467","media":"Zacks","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490862467?lang=en_us&edition=fundamental","pubTime":"2024-12-11 23:02","pubTimestamp":1733929320,"startTime":"0","endTime":"0","summary":"uniQure N.V.QURE surged 109.7% after it announced reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130, a one-time administered investigational gene therapy, which is being developed to treat Huntington’s disease.Huntington's disease is a genetic disorder that causes the progressive breakdown of nerve cells in the brain, which leads to a decline in cognitive and physical abilities, often resulting in movement, thinking and psychiatric problems. uniQure enjoys the FDA’s Regenerative Medicine Advanced Therapy  designationfor AMT-130 to treat Huntington’s disease.uniQure is simultaneously conducting two phase I/II studies of AMT-130, with 26 participants in the United States and 13 in the EU/UK to treat Huntington's disease. Among these, a total of 29 patients received either a low dose  or a high dose  of","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/woEWcNDZGH_3gLX_.sdY1g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/woEWcNDZGH_3gLX_.sdY1g--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/qure-soars-fda-alignment-speedy-150200885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","SG9999002224.SGD","SG9999003800.SGD","SG9999002232.USD","QURE","LU0058720904.USD","SG9999001176.SGD","IE0002270589.USD","LU0109394709.USD","IE00B19Z3B42.SGD","BK4550","BK4588","LU0234570918.USD","LU1430594728.SGD","LU1066053197.SGD","LU2468319806.SGD","LU0225284248.USD","LU1023059063.AUD","LU1057294990.SGD","IE000M9KFDE8.USD","LU2087621335.USD","LU1571399168.USD","CSF","IE00B7SZLL34.SGD","BK4581","IE00B3T34201.USD","BK4534","LU1585245621.USD","LU1839511570.USD","LU0234572021.USD","BK4599","BK4578","LU0321505439.SGD","LU0985481810.HKD","ALNY","IE00BBT3K403.USD","BK4532","BK4533","GILD","IE00BKVL7J92.USD","LU0306806265.USD","LU1894683264.USD","PFE","SG9999011175.SGD","BK4568","IE00BLSP4239.USD","LU0321505868.SGD","LU0306807586.USD","LU0225771236.USD","SGXZ57979304.SGD"],"gpt_icon":1},{"id":"2490239094","title":"uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2490239094","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490239094?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:05","pubTimestamp":1733832300,"startTime":"0","endTime":"0","summary":"~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Applica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/10/2994386/0/en/uniQure-Announces-Alignment-with-FDA-on-Key-Elements-of-Accelerated-Approval-Pathway-for-AMT-130-in-Huntington-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","QURE","BK4219","BK4084","BK4588","BK4581","AMT","CSF","BK4534","BK4139","BK4554"],"gpt_icon":0},{"id":"2489220997","title":"Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2489220997","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489220997?lang=en_us&edition=fundamental","pubTime":"2024-12-08 01:00","pubTimestamp":1733590800,"startTime":"0","endTime":"0","summary":"73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months. NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve  0-15 days post-administration being 5.8-fold greater than placebo-controls. In this multicenter, double-blind Phase 2 study, patients were randomized to receive one of three dose regimens of NKTR-255 or placebo intravenously starting 14 days after CAR-T infusion. In the fifteen-person clinical trial, the NKTR-255 combined treatment group demonstrated an improved CRR at six months, achieving 73% compared to 50% for the placebo, as assessed by a blinded independent central radiology review. Additionally, two patients treated with NKTR-255 converted from stable disease or partial response to complete responses at six months. No conversions from stable disease or partial response to complete response were observed in the placebo arm of the trial.\"This study is the first randomized trial demons","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-nktr-255-170000373.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-nktr-255-170000373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","BK4109","CSF","BK4230","LU2463526074.USD","ASH","BK4022","NKTR","BK4007"],"gpt_icon":0},{"id":"2488595160","title":"Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2488595160","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488595160?lang=en_us&edition=fundamental","pubTime":"2024-12-04 20:30","pubTimestamp":1733315400,"startTime":"0","endTime":"0","summary":"Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec.  04, 2024  (GLOBE N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/04/2991382/0/en/Plus-Therapeutics-to-Showcase-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-San-Antonio-Breast-Cancer-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","NCI","CSF","BK4202","BK4135","BK4139","LENZ"],"gpt_icon":0},{"id":"2488978501","title":"Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2488978501","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488978501?lang=en_us&edition=fundamental","pubTime":"2024-12-04 02:37","pubTimestamp":1733251020,"startTime":"0","endTime":"0","summary":"Novartis NVS has entered into a global license and collaboration agreement with PTC Therapeutics PTCT for the latter’s Huntington's disease candidate to strengthen NVS’ neuroscience pipeline.NVS also announced a collaboration with Olema Pharmaceuticals, Inc. OLMA for a breast cancer drug.Year to date, shares of Novartis have risen 3.8% compared with the industry’s growth of 8.9%.Novartis will in-license PTC Therapeutics’ PTC518. The candidate is an oral disease-modifying therapy in development for Huntington's disease.Interim results, reported in June 2024, demonstrated that PTC518 treatment resulted in durable, dose-dependent reduction in blood and cerebrospinal fluid  mutant Huntingtin protein  levels as well as early signals of dose-dependent benefit on key clinical measurements at 12 months.Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in development, regulatory and sales milestones. NVS will also share pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1GILAZNg_sZU4tvhUip3sw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1GILAZNg_sZU4tvhUip3sw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-licenses-ptcts-huntingtons-disease-183700510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","LU0306807586.USD","LU0211331839.USD","LU0456855351.SGD","BK4532","LU0985481810.HKD","LU1066051498.USD","IE00BLSP4452.SGD","BK4585","BK4599","LU1894683264.USD","IE0002141913.USD","SGXZ57979304.SGD","LU0109394709.USD","IE00BBT3K403.USD","LU1894683348.USD","BK4581","BK4139","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","IE00B4R5TH58.HKD","LU1883839398.USD","BK4007","LU0225284248.USD","SG9999013999.USD","IE000M9KFDE8.USD","PTCT","CSF","IE0002270589.USD","IE0009355771.USD","LU0225771236.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","IE00BJT1NW94.SGD","SG9999003800.SGD","BK4568","LU1023059063.AUD","LU0122379950.USD","OLMA","PFE","BK4592","NVS","SG9999002232.USD","LU0321505868.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD"],"gpt_icon":1},{"id":"2488674028","title":"Press Release: Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem","url":"https://stock-news.laohu8.com/highlight/detail?id=2488674028","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488674028?lang=en_us&edition=fundamental","pubTime":"2024-12-02 22:30","pubTimestamp":1733149800,"startTime":"0","endTime":"0","summary":"Ampersand Capital Partners Completes Acquisition of Nektar Therapeutics' PEG Reagent Manufacturing Business, Launching Newly Branded Gannet BioChem. BOSTON and HUNTSVILLE, Ala., Dec. 2, 2024 /PRNewswire/ -- Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of its previously announced acquisition of Nektar Therapeutics' PEGylation reagent manufacturing business. The new Ampersand portfolio company will be branded Gannet BioChem and will continue to operate out of its state-of-the-art facility in Huntsville, Alabama.\"We are thrilled to introduce Gannet BioChem as a new, independent PEG reagents CDMO,\" said David Anderson, General Partner at Ampersand Capital Partners. \"The PEG reagent manufacturing team at Gannet BioChem has a well-established track record and long history of delivering high-quality, specialized PEG reagents for commercial and clinical stage biolo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BD4GTW91.USD","NKTR","IE00BMG7P926.USD","BK4585","BK4007","IE00BMG7P694.USD","IE00BMG7P819.SGD","CSF","BK4208","IE00BD4GTV84.USD","PEG","IE00BMG7P587.USD","IE00BD4GTT62.SGD"],"gpt_icon":0},{"id":"2486855110","title":"Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486855110","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486855110?lang=en_us&edition=fundamental","pubTime":"2024-11-25 20:30","pubTimestamp":1732537800,"startTime":"0","endTime":"0","summary":"Single intrathecal dose of Rhenium (186Re) Obisbemeda shows a favorable response rate and median overall survival in leptomeningeal metastases (LM) patients Achieves up to 8x absorbed radiation dose t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/25/2986577/0/en/Plus-Therapeutics-Presents-Positive-ReSPECT-LM-Phase-1-Interim-Data-for-Leptomeningeal-Metastases-at-the-2024-SNO-Annual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","LENZ","BK4139","NCI","BK4202"],"gpt_icon":0},{"id":"2485498812","title":"Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2485498812","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485498812?lang=en_us&edition=fundamental","pubTime":"2024-11-21 20:30","pubTimestamp":1732192200,"startTime":"0","endTime":"0","summary":"CNSide Cerebrospinal Fluid (CSF) Assay analyzed 258 CSF samples across 66 leptomeningeal metastases (LM) patients at five institutions CNSide identified extensive, actionable mutational changes, and c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/21/2985113/0/en/Plus-Therapeutics-to-Present-Multi-Institutional-Experience-Using-the-CNSide-Cerebrospinal-Fluid-Assay-in-Patients-with-Leptomeningeal-Metastases.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","NCI","BK4179","BK4202","NGS","CSF"],"gpt_icon":0},{"id":"2484985090","title":"Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence","url":"https://stock-news.laohu8.com/highlight/detail?id=2484985090","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484985090?lang=en_us&edition=fundamental","pubTime":"2024-11-19 04:30","pubTimestamp":1731961800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics  today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology conference, being held in Washington, D.C. from November 14-19, 2024.Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin , is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rtboK12ORMgNOQ6pHWHlMg--~B/aD04Mzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ed402d287488a53ce89b92f9b5ed2bb0"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-presents-first-preclinical-203000192.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-presents-first-preclinical-203000192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AFG","BK4110","BK4007","LU1169590202.USD","LU1169589451.USD","BK4218","PD","NKTR","CSF","BK4181","ACR","PK","BK4107","BK4023","BK4117"],"gpt_icon":0},{"id":"2483809759","title":"ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483809759","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483809759?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:15","pubTimestamp":1731593700,"startTime":"0","endTime":"0","summary":"Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981299/0/en/ProMIS-Neurosciences-Announces-Third-Quarter-2024-Financial-Results-and-Recent-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU1815336091.USD","BK4143","PK","CSF","MSA","BK4181","BK4218","LU0757428866.USD","LU2125909759.SGD","BK4110","AAIC","LU2125909916.SGD","LU0728928796.USD","LU1923622291.USD"],"gpt_icon":0},{"id":"2483800914","title":"IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant","url":"https://stock-news.laohu8.com/highlight/detail?id=2483800914","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483800914?lang=en_us&edition=fundamental","pubTime":"2024-11-14 21:21","pubTimestamp":1731590460,"startTime":"0","endTime":"0","summary":"Integra LifeSciences Holding Corporation IART has announced the publication of a new economic study assessing the budget impact of switching treatment from fibrin glue to DuraSeal Polyethylene Glycol  hydrogel in five major European countries. The findings show an average cost savings of 419 to 1,279 per patient, with a consistent cost reduction averaging around 22% per procedure across Belgium, France, Germany and the United Kingdom, and 15% in Italy.The study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries,” was published in the Journal of Comparative Effectiveness Research in February 2024.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/iart-stock-gain-study-findings-132100765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2506952097.USD","LU1061106388.HKD","LU1791710582.SGD","LU0353189763.USD","LU2362540622.SGD","BK4581","LU0048584097.USD","LU0077335932.USD","HAE","IE00B64QTZ34.USD","LU0187121727.USD","LU1057294990.SGD","LU0114720955.EUR","LU0266013472.USD","LU0345769128.USD","LU2491050071.SGD","LU2324357040.USD","LU2491050154.USD","GMED","LU0012050646.USD","LU2506952170.USD","IE0002141913.USD","LU0823417737.USD","LU2362541513.USD","LU0267386448.USD","LU1791710400.SGD","LU1989772923.USD","BK4198","LU1291159041.SGD","LU1023059063.AUD","IE00BJT1NW94.SGD","LU2244417387.USD","LU1989771016.USD","PCF","IART","BSX","LU1718418525.SGD","IE00BJJMRZ35.SGD","LU2087625088.SGD","LU0205193047.USD","BK4588","LU0345769631.USD","LU0950375773.USD","LU1989764664.SGD","LU0106261612.USD","LU1804176565.USD","IE00BLDYK493.USD","CSF","LU0882574055.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2482705399","title":"Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2482705399","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482705399?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier.Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Book Value Per Share was $25.32 for the quarter ended September 30, 2024 as compared to $23.88 at September 30, 2023.One HMCA-managed MRI scanner was added in the first quarter of fiscal 2024, bringing the total number of managed scanners to 43.On September 13, 2022, the Company adopted a stock repurchase plan of up to $9 million. At September 30, 2024, the Company has purchased over 283,770 shares at a cost of $4,680,889.Revenues from the FONAR segment, which includes Product Sales, Upgrades, Service and Repair Fees, for related and non-related medical parties, increased 5% to $2.2 million for the quarter ended September 30, 2024, as compared to $2.1 million for the quarter ended September 30","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/xsCVO6rGH3WT0PKoguKJDg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/431fd10559b014e75a70a9e82fe585b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/xsCVO6rGH3WT0PKoguKJDg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/431fd10559b014e75a70a9e82fe585b8"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fonar-announces-financial-results-1st-120000412.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fonar-announces-financial-results-1st-120000412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FONR","NMR","CSF","BK4552","BK4082","BK4127"],"gpt_icon":0},{"id":"2481922311","title":"Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2481922311","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481922311?lang=en_us&edition=fundamental","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025. Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors expected to initiate by year-end, with topline results anticipated in H2 2025. Cash balance of $274.8M as of September 30, 2024 expected to fund operations into at least H2 2026. “Thanks to the continued execution of our team, we are on track to initiate a Phase 2 trial of VTX2735 in recurrent pericarditis and a Phase 2 obesity and cardiometabolic trial of VTX3232 by the end of this year, in addition to advancing enrollment in the ongoing Phase 2a trial of VTX3232 in patients with early Parkinson’s disease,” said Raju Mohan, PhD, President and Chief Executive Officer. “With our potential best-in-class NLRP3 inhibitors, we believe we are well positioned to unlock the vast therapeutic potential of the inflammasome pathway.”VTX2735 : We expect to initiate a Phase 2 trial of VTX2735 in participa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Jc2yXxL2ot4T9jD4KxC8DA--~B/aD0xMTM0O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/12b40026a3fa9d74aa047df3c485d3a1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Jc2yXxL2ot4T9jD4KxC8DA--~B/aD0xMTM0O3c9NDAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/12b40026a3fa9d74aa047df3c485d3a1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ventyx-biosciences-reports-third-quarter-210500318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4139","BK4097","PRGS","VTYX","CAPS","LU2065732104.USD","CSF"],"gpt_icon":0},{"id":"2481190597","title":"Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481190597","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481190597?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"On track to initiate a Phase 3 program for Company’s lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia  in the first quarter of 2025. Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures at Week 24 and sustained improvement at Weeks 36 and 48. Cash, cash equivalents and marketable securities of $234.4 million as of September 30, 2024; cash runway expected into 2026. Management to host conference call and webcast today at 8:00 a.m. Eastern Time","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/R6mWST0Uiw5I72IajriwwA--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/570450fc193c48c5d1e5b851819c3ede","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/R6mWST0Uiw5I72IajriwwA--~B/aD01ODg7dz0yNTE3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/570450fc193c48c5d1e5b851819c3ede"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amylyx-pharmaceuticals-reports-third-quarter-120000575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2360032135.SGD","PBH","AMLX","LU0029874061.USD","BK4161","HI","LU2125154778.USD","CSF","BK4007","BK4211","PB","PSP","LU2125154935.USD","LU0128526141.USD"],"gpt_icon":0},{"id":"2481460614","title":"Press Release: Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2481460614","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481460614?lang=en_us&edition=fundamental","pubTime":"2024-11-06 21:00","pubTimestamp":1730898000,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell  function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024.-- Announced positive results from an investigator initiated double-blind. study of low-dose interleukin-2  in patients with mild to. moderate Alzheimer's Disease  at the Clinical Trials on Alzheimer's. -- Filed patents for COYA 301 in combination with Glucagon-Like Peptide-1. -- Promoted Arun Swaminathan, Ph.D. to Chief Executive Officer, effective. November 1, 2024, while Howard Berman has transitioned from CEO to. -- Announced anti-inflammatory effects of COYA 302 in the brain from a. -- Aligned with FDA on the non-clinical data needed to support the planned. randomized, double-blind, placebo-controlled, Phase 2b trial of COYA-302. -- A Phase 1 investigator-initiated trial  combining LD IL-2 + CTLA4-Ig. investigator-initiated trial  study in pati","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","PD","BK4139","COYA","LENZ","BK4023","LU1169589451.USD","LU1169590202.USD"],"gpt_icon":0},{"id":"2481960863","title":"Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2481960863","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481960863?lang=en_us&edition=fundamental","pubTime":"2024-11-06 20:00","pubTimestamp":1730894400,"startTime":"0","endTime":"0","summary":"– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer  and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development –。– Multiple TNG462 combination studies planned in 1H 2025 –。– Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS multi- and G12D-selective inhibitors –。– TNG456, a next-generation brain penetrant MTA-cooperative PRMT5 inhibitor with enhanced potency and MTAP-deleted-selectivity, entering phase 1/2 clinical trial 1H 2025 to be evaluated both as a monotherapy and in combination with CDK4/6 inhibitor abemaciclib –。\"Clinical data from the phase 1/2 trial demonstrate that TNG462 has potentially best-in-class chara","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rG3X5ErJLm7G3H0HggZsSA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/14b432ed2e029fb292ff65581b3206cb","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rG3X5ErJLm7G3H0HggZsSA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/14b432ed2e029fb292ff65581b3206cb"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tango-therapeutics-reports-positive-tng462-120000174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1978683503.SGD","ON","LU1861214812.USD","TNGX","LU1548497426.USD","LU1861220033.SGD","LU1720051108.HKD","LU1854104046.USD","BK4512","LU2357305700.SGD","BK4141","CSF","LU2360107325.USD","LU0124384867.USD","LU2298322129.HKD","LENZ","IE00BD6J9T35.USD","BK4588","LU1861215975.USD","IE00BZ199S13.USD","LU1861219969.SGD","LU0348723411.USD","LU1720051017.SGD","BK4585","BK4139","LU0724618433.USD","LU1854103824.USD"],"gpt_icon":1},{"id":"2481307570","title":"uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2481307570","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481307570?lang=en_us&edition=fundamental","pubTime":"2024-11-05 20:05","pubTimestamp":1730808300,"startTime":"0","endTime":"0","summary":"~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~ Prese","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/05/2974805/0/en/uniQure-Announces-Third-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","QURE","PRGS","BK4097","CSF","BK4139"],"gpt_icon":1}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"},{"date":"2024-10-08","symbol":"CSF","amount":0.052247,"announcedDate":"2024-10-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-08","defaultRemindTime":1728394200000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-09","payableDate":"2024-10-08","currency":"USD","dateTimestamp":1728360000000,"payDate":"2024-10-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-16","recordDate":"2015-06-18","paymentDate":"2015-06-19","value":0.0849404,"currency":"USD"},{"executeDate":"2015-09-22","recordDate":"2015-09-24","paymentDate":"2015-09-25","value":0.0863264,"currency":"USD"},{"executeDate":"2015-12-28","recordDate":"2015-12-30","paymentDate":"2015-12-31","value":0.1258576,"currency":"USD"},{"executeDate":"2016-03-08","recordDate":"2016-03-10","paymentDate":"2016-03-11","value":0.0228347,"currency":"USD"},{"executeDate":"2016-06-14","recordDate":"2016-06-16","paymentDate":"2016-06-17","value":0.0798989,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{}}}